Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Choosing an annual fee credit card can be advantageous in certain situations. Understand when it's worth the investment for greater rewards.
13,041 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
A fit, mid-60s couple reevaluates when to claim Social Security as Treasury yields hover near 4.5%, blending safe inc...
Two cloud industry veterans face off as AI accelerates enterprise IT. This guide weighs growth, risk, and value to an...
Apple sidesteps the AI capex race, prioritizing software and on-device AI. Analysts see a bigger iPhone upgrade cycle...
In mid-2026 market conditions test retirement plans built on dividend income. This piece weighs yield versus growth t...
Oracle stock down 60% from its peak doesn’t tell the whole story. This article digs into the AI cloud momentum fuelin...
SpaceX is the darling of space dreams and bold tech bets. This article breaks down what it would take for a public Sp...
When a top executive sells stock, investors want to know if it signals trouble or simply personal planning. This arti...
Retirees with a $2 million 401(K) who buy a QLAC may shift their RMDs, potentially triggering higher tax rates and Me...
When a board member sells 7,000 shares, traders and long-term investors want to know why. This article breaks down Fo...
Small-cap growth has propelled some funds to the top this year. Discover the overlooked Vanguard outpacing this rally...
Imagine a space tech powerhouse going public and shaping Wall Street expectations. This article lays out three plausi...